文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

不成比例继发性二尖瓣反流:误区、误解与临床意义

Disproportionate secondary mitral regurgitation: myths, misconceptions and clinical implications.
PubMed 文献 · Heart · 2020-11-24

继发性二尖瓣反流(SMR)常继发于左心室(LV)扩张或功能障碍。不成比例严重SMR的概念用于解释经导管缘对缘二尖瓣修复(TEER)与药物治疗两项随机试验的不同结果,其基于有效反流口面积(EROA)取决于LV舒张末期容积(LVEDV)、射血分数、反流分数和SMR速度时间积分。本综述聚焦该概念的血流动力学框架及由此产生的误区与误解。

要点

  • EROA/LVEDV比值强调评估MR严重程度需考虑LV大小和功能,并有助于解释COAPT与MITRAFR的不同结局。
  • EROA各组分易出现测量误差,可能导致个体患者误分类。
  • EROA通常在收缩峰值测量而非MR持续时间内的平均值,可能产生生理上不可能的EROA或反流体积值。

核心结论

  • EROA/LVEDV比值有助于解释COAPT与MITRAFR的不同结局,但未纳入左房顺应性、LV压力和射血分数、肺动脉高压、右心室功能和三尖瓣反流等重要因素。

研究设计与样本

  • 本文为综述,聚焦不成比例严重SMR概念的血流动力学框架及由此产生的误区与误解。

主要发现

  • EROA取决于LVEDV、射血分数、反流分数和SMR速度时间积分。
  • EROA/LVEDV比值强调评估MR严重程度需考虑LV大小和功能,并有助于解释COAPT与MITRAFR的不同结局。
  • EROA各组分易出现测量误差,可能导致个体患者误分类。
  • EROA通常在收缩峰值测量而非MR持续时间内的平均值,可能产生生理上不可能的EROA或反流体积值。
  • 左房顺应性、LV压力和射血分数、肺动脉高压、右心室功能和三尖瓣反流等因素未纳入EROA/LVEDV比值。

临床怎么用

  • 药物治疗可减少LV容积并改善LV功能和SMR严重程度,患者选择的关键是神经激素拮抗剂强制滴定至临床试验证实的靶剂量,并在适当时候进行心脏再同步化治疗。
  • 在优化药物治疗后仍有症状性严重SMR的患者应考虑TEER。

局限性

  • EROA各组分易出现测量误差,可能导致个体患者误分类。
  • EROA通常在收缩峰值测量而非MR持续时间内的平均值,可能产生生理上不可能的EROA或反流体积值。
  • EROA/LVEDV比值未纳入左房顺应性、LV压力和射血分数、肺动脉高压、右心室功能和三尖瓣反流等重要因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary (functional) mitral regurgitation (SMR) most commonly arises secondary to left ventricular (LV) dilation/dysfunction. The concept of disproportionately severe SMR was proposed to help explain the different results of two randomised trials of transcatheter edge-to-edge mitral valve repair (TEER) versus medical therapy. This concept is based on the fact that effective regurgitant orifice area (EROA) depends on LV end-diastolic volume (LVEDV), ejection fraction, regurgitant fraction and the velocity-time integral of SMR. This review focuses on the haemodynamic framework underlying the concept and the myths and misconceptions arising from it. Each component of EROA/LVEDV is prone to measurement error which can result in misclassification of individual patients. Moreover, EROA is typically measured at peak systole rather than its mean value over the duration of MR. This can result in physiologically impossible values of EROA or regurgitant volume. Although the EROA/LVEDV ratio (1) emphasises that grading MR severity needs to consider LV size and function and (2) helps explain the different outcomes between COAPT and MITRAFR, there are important factors that are not included. Among these are left atrial compliance, LV pressure and ejection fraction, pulmonary hypertension, right ventricular function and tricuspid regurgitation. Because medical therapy can reduce LV volumes and improve both LV function and SMR severity, the key to patient selection is forced titration of neurohormonal antagonists to the target doses that have been proven in clinical trials (along with cardiac resynchronisation when appropriate). Patients who continue to have symptomatic severe SMR after doing so should be considered for TEER.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Grayburn PA, Packer M, Sannino A, et al. Disproportionate secondary mitral regurgitation: myths, misconceptions and clinical implications. Heart. 2020. PMID: 33234674. doi:10.1136/heartjnl-2020-316992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。